Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksExperian Regulatory News (EXPN)

Share Price Information for Experian (EXPN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3,244.00
Bid: 3,243.00
Ask: 3,245.00
Change: -13.00 (-0.40%)
Spread: 2.00 (0.062%)
Open: 3,262.00
High: 3,272.00
Low: 3,238.00
Prev. Close: 3,257.00
EXPN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Experian agrees to acquire Compuscan

10 Dec 2018 13:30

RNS Number : 9966J
Experian plc
10 December 2018
 

 

news release

 

 

Experian agrees to acquire Compuscan, extending our bureau presence in Africa

 

10 December 2018 - Experian, the global information services company, is pleased to announce that it has agreed to acquire Compuscan (CSH Group (Pty) Limited), one of the leading credit bureau and information services businesses in Africa.

 

Brian Cassin, Chief Executive Officer said:

 

"We are delighted to announce that Experian has agreed to acquire Compuscan. We have a long track record of investment in South Africa, where for many years we have helped businesses thrive through the provision of credit data and decisioning tools. Millions of people across Africa need access to financial services. By combining forces with Compuscan, we will be better positioned to serve the people and businesses of this region and be an enabler of growth in consumer and business credit, identity management and financial inclusion. This is an important transaction for our business in South Africa and will provide opportunities more broadly across the African continent. We look forward to welcoming the Compuscan team to Experian."

 

Overview of Compuscan

 

Founded in 1994, Compuscan is one of the leading providers of credit information and decision analytics in South Africa, with operations across seven key geographies in Sub-Saharan Africa. Compuscan also provides marketing services and has recently launched a free credit report service for consumers.

 

By combining Experian and Compuscan, we will enhance the services we can provide to our B2B customers and consumers, as well as delivering substantial operational synergies. In addition to deepening our bureau data assets, Compuscan has particular strength in analytics and scores, which is highly complementary to Experian's strength in decisioning software. We will also be better positioned to leverage our continuing investment in innovation to combine the best of Experian with that of Compuscan to bring the latest and most competitive credit assessment tools to the African market. For example, we have recently introduced our big data analytics platform Ascend to financial services and telecommunications clients in South Africa and likewise see potential to expand Compuscan's nascent position in providing services to consumers. Compuscan holds credit information on 26 million people and 200,000 businesses in South Africa, representing approximately 56% of the population.

 

The combined customer bases will also be highly complementary. Experian's customers in South Africa are mainly large financial institutions and telecommunications operators, while Compuscan has an attractive position in the dynamic microlending space, as well as in the retail and insurance sectors.

 

Financial information

 

We have agreed to acquire 100% of Compuscan for a cash consideration of R3,720m (c.US$263m*) payable on completion. The transaction is expected to be funded from existing cash resources. The transaction is subject to approval by the Competition Commission in South Africa. It is expected to complete during the first quarter of financial year ending 31 March 2020.

 

For the year ending 31 December 2018, Compuscan is expected to generate R489 million (US$35 million) in revenue, growing to R532 million (US$38 million) in the year ending 31 December 2019. This compares to Experian revenues in South Africa of around US$40m. We expect the transaction to be accretive to Benchmark EPS in its first full year of ownership.

 

* ZAR/US$ exchange rate of 14.17 as at 10 December 2018.

Contact:

Experian

Nadia Ridout-Jamieson Investors +44 (0)20 3042 4215

Gerry Tschopp Media +1 714 830 7756

 

Finsbury

Rollo Head +44 (0)20 7251 3801

Jenny Davey

 

About Experian

Experian is the world's leading global information services company. During life's big moments - from buying a home or a car, to sending a child to college, to growing a business by connecting with new customers - we empower consumers and our clients to manage their data with confidence. We help individuals to take financial control and access financial services, businesses to make smarter decisions and thrive, lenders to lend more responsibly, and organisations to prevent identity fraud and crime.

 

We have 16,500 people operating across 39 countries and every day we're investing in new technologies, talented people and innovation to help all our clients maximise every opportunity. We are listed on the London Stock Exchange (EXPN) and are a constituent of the FTSE 100 Index.

 

Learn more at www.experianplc.com or visit our global content hub at our global news blog for the latest news and insights from the Group.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQEADAEFFLPFFF
Date   Source Headline
31st May 20239:32 amRNSAdditional Listing
22nd May 202312:46 pmRNSDirector/PDMR Shareholding
18th May 20232:29 pmRNSDirector/PDMR Shareholding
18th May 202310:20 amRNSDirector/PDMR Shareholding
17th May 20234:00 pmRNSDirector/PDMR Shareholding
17th May 202311:00 amRNSShare repurchases
17th May 20237:00 amRNSFull-year financial report
28th Apr 202310:15 amRNSTotal Voting Rights
12th Apr 20239:30 amRNSAdditional Listing
4th Apr 20239:45 amRNSAdditional Listing
31st Mar 202311:35 amRNSTotal Voting Rights
29th Mar 20239:20 amRNSAdditional Listing
28th Mar 20237:00 amRNSDirectorate Change
22nd Mar 20235:19 pmRNSTransaction in Own Shares
22nd Mar 20239:15 amRNSAdditional Listing
20th Mar 20235:18 pmRNSTransaction in Own Shares
17th Mar 20235:31 pmRNSTransaction in Own Shares
16th Mar 20235:09 pmRNSTransaction in Own Shares
16th Mar 20239:15 amRNSBlock listing Interim Review
15th Mar 20235:14 pmRNSTransaction in Own Shares
15th Mar 20239:15 amRNSAdditional Listing
14th Mar 20235:21 pmRNSTransaction in Own Shares
13th Mar 20235:31 pmRNSTransaction in Own Shares
10th Mar 20236:10 pmRNSTransaction in Own Shares
9th Mar 20235:22 pmRNSTransaction in Own Shares
8th Mar 20235:21 pmRNSTransaction in Own Shares
8th Mar 20239:15 amRNSAdditional Listing
7th Mar 20235:26 pmRNSTransaction in Own Shares
1st Mar 202312:00 pmRNSDirector/PDMR Shareholding
1st Mar 20239:15 amRNSAdditional Listing
28th Feb 202312:20 pmRNSTotal Voting Rights
22nd Feb 202310:00 amRNSAdditional Listing
15th Feb 202310:45 amRNSAdditional Listing
10th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20239:30 amRNSAdditional Listing
1st Feb 20239:15 amRNSAdditional Listing
31st Jan 20232:30 pmRNSDirector Declaration
31st Jan 202310:15 amRNSTotal Voting Rights
25th Jan 20239:15 amRNSAdditional Listing
17th Jan 20237:00 amRNSExperian Q3 FY23 trading update
13th Jan 20235:20 pmRNSFirst interim dividend
9th Jan 20237:00 amRNSDirectorate Change
30th Dec 202210:15 amRNSTotal Voting Rights
16th Dec 202211:30 amRNSElections for first interim dividend
14th Dec 20229:15 amRNSAdditional Listing
7th Dec 20229:00 amRNSAdditional Listing
30th Nov 202211:59 amRNSTotal Voting Rights
16th Nov 20227:00 amRNSHalf-year Report
31st Oct 20229:30 amRNSTotal Voting Rights
14th Oct 20229:51 amRNSShare Repurchase Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.